DecImmune Therapeutics Lands $1,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3ed8cea5-66b7-40f0-86bb-6c55c76ed3f9&Preview=1 - Date
9/27/2010 - Company Name
DecImmune Therapeutics - Mailing Address
One Blackfan Circle Rm. 10217 Boston, MA 02115 - Company Description
The company operates as a drug development company focused on inflammation. - Website
http://www.decimmune.com - Transaction Type
Venture Equity - Transaction Amount
$1,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
The new funds will enable accelerated development of the company’s proprietary technology to reduce tissue damage, accelerate healing, and improve outcomes associated with ischemia reperfusion injury. - M&A Terms
- Venture Investor
Astellas Venture Management LLC - Venture Investor
HealthCare Ventures - Venture Investor
Amgen Ventures
